SAN DIEGO–(BUSINESS WIRE)–$EVFM #sayvagina–Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) today announced the launch of the Say Vagina StoreSAN DIEGO–(BUSINESS WIRE)–$EVFM #sayvagina–Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) today announced the launch of the Say Vagina Store

Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store

SAN DIEGO–(BUSINESS WIRE)–$EVFM #sayvagina–Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) today announced the launch of the Say Vagina Store, expanding its groundbreaking Say Vagina campaign aimed at normalizing accurate anatomical language and advancing education and autonomy in women’s health.

Say Vagina is an ongoing initiative designed to address the widespread censorship of proper female anatomical terms in the media, where algorithms often equate educational language with explicit content and related content is secretly buried — shadow-banned,” said Saundra Pelletier, CEO of Evofem Biosciences. “We aim to replace silence with strength, transforming shame into empowerment through language normalization. The Say Vagina Store extends this mission by reinforcing the importance of accurate, uncensored health communication.”

Originally launched in August 2025, the Say Vagina campaign was created to address the widespread censorship of essential medical terminology across digital platforms and media channels. The initiative seeks to improve public understanding of women’s health by promoting clear, clinical language and reducing stigma that can impede education and access to care.

The Say Vagina Store serves as an extension of the campaign’s educational and advocacy efforts, offering a dedicated platform that supports awareness, dialogue, and cultural change in women’s health.

Evofem’s broader philosophy calls for rewiring women’s health, prioritizing transparency over persuasion, education over fear, and respect over control. This approach informs how the Company thinks about innovation, evidence generation, and patient choice across women’s healthcare.

The Say Vagina campaign continues to gain national visibility and will be further amplified in 2026 at SXSW with a featured panel titled “Say Vagina: Platform Censorship, Algorithms, and the Cost to Women’s Health.” The panel will explore how digital censorship and algorithmic suppression of clinical language can negatively impact health education, patient outcomes, and innovation in women’s health.

“More than half the population has a vagina, but its proper anatomical name remains heavily censored and stigmatized. Saying ‘vagina’ is not provocative,” Pelletier added. “Silencing women is.”

The Say Vagina Store can be accessed at www.SayVaginaStore.com.

About Evofem Biosciences

Evofem Biosciences, Inc. is commercializing two FDA-approved sexual and reproductive health products:

  • PHEXX® (lactic acid, citric acid, and potassium bitartrate) – the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexx.com to learn more and for important safety information.
  • SOLOSEC® (secnidazole) 2 g oral granules – an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.

PHEXX® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

Contacts

Media Contact
[email protected]

Investor & Business Development Contact
Amy Raskopf

Evofem Biosciences, Inc.

[email protected]
(917) 673-5775

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$0.7057
$0.7057$0.7057
+3.74%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

MAXI DOGE Holders Diversify into $GGs for Fast-Growth 2025 Crypto Presale Opportunities

MAXI DOGE Holders Diversify into $GGs for Fast-Growth 2025 Crypto Presale Opportunities

Presale crypto tokens have become some of the most active areas in Web3, offering early access to projects that blend culture, finance, and technology. Investors are constantly searching for the best crypto presale to buy right now, comparing new token presales across different niches. MAXI DOGE has gained attention for its meme-driven energy, but early [...] The post MAXI DOGE Holders Diversify into $GGs for Fast-Growth 2025 Crypto Presale Opportunities appeared first on Blockonomi.
Share
Blockonomi2025/09/18 00:00
Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

Bank of Canada cuts rate to 2.5% as tariffs and weak hiring hit economy

The Bank of Canada lowered its overnight rate to 2.5% on Wednesday, responding to mounting economic damage from US tariffs and a slowdown in hiring. The quarter-point cut was the first since March and met predictions from markets and economists. Governor Tiff Macklem, speaking in Ottawa, said the decision was unanimous. “With a weaker economy […]
Share
Cryptopolitan2025/09/17 23:09
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23